Overview
- Blood cancer specialist who treats myeloid neoplasm including acute leukemias, myelodysplastic syndrome, myeloproliferative neoplasm, chronic myeloid leukemia.
- Cellular therapy specialist with interests in allogeneic hematopoietic cell transplantation and survivorship care.
- Health services researcher investigating social factors influencing access to and outcomes of treatment for hematologic malignancies.
- Cellular therapy specialist with interests in allogeneic hematopoietic cell transplantation and survivorship care.
- Health services researcher investigating social factors influencing access to and outcomes of treatment for hematologic malignancies.
Current Duke Appointments & Affiliations
Assistant Professor of Medicine
·
2022 - Present
Medicine, Hematologic Malignancies and Cellular Therapy,
Medicine
Assistant Professor in Population Health Sciences
·
2024 - Present
Population Health Sciences,
Basic Science Departments
Member of the Duke Cancer Institute
·
2022 - Present
Duke Cancer Institute,
Institutes and Centers
Recent News Items
View All News Items
Recent Scholarly Works
Infections within 100 days of idecabtagene vicleucel and impact on survival for relapsed/refractory multiple myeloma: A CIBMTR Analysis.
Journal article Transplant Cell Ther · June 27, 2026 BACKGROUND: Infections are common after chimeric antigen receptor (CAR) T-cell therapy and contribute to morbidity and mortality. While well characterized with CD19 CAR T-cells, data related to infections with B-cell maturation antigen (BCMA) CAR T-cell th ... Full text Link to item CiteSociodemographic factors and timing of allogeneic hematopoietic stem cell transplantation in myeloproliferative neoplasms.
Journal article Bone Marrow Transplant · June 2026 Full text Link to item CiteImpact of donor age on cognitive recovery in allogenic hematopoietic stem cell transplant patients with mild cognitive impairment.
Journal article Bone Marrow Transplant · June 2026 Full text Link to item CiteRecent Grants
Abatacept for Omidubicel Transplant
Clinical TrialPrincipal Investigator · Awarded by Gamida Cell Inc. · 2025 - 2030A Randomized, Multicenter, Phase III Trial of Tacrolimus/Methotrexate/Ruxolitinib versus Post-Transplant Cyclophosphamide/Tacrolimus/Mycophenolate Mofetil in Non-Myeloablative/Reduced Inten
Clinical TrialPrincipal Investigator · Awarded by National Marrow Donor Program · 2025 - 2030A Phase 1, Open-label, Preliminary Pharmacokinetics (PK) and Safety Study of CLN-049 (An fms-like tyrosine kinase 3 [FLT3] x cluster of differentiation 3 [CD3] bispecific T cell engager) in Patients with Relapsed/Refractory Acute Myeloid Leukemia (A
Clinical TrialPrincipal Investigator · Awarded by Cullinan Florentine Corporation · 2024 - 2029View All Grants
Education
Medical College of Wisconsin ·
2014
M.D.